Rechts der Isar Hospital of the Technical University Munich

The outpatient clinics for motoneuron diseases is part of the Department of Neurology of the rechts der Isar Hospital, at the Technical University of Munich. Every year, we have approximately 400 patient visits and care for approximately 150 patients. We diagnose and treat patients with a broad spectrum of motor neuron diseases, but especially patients with ALS and SMA. In addition to state-of-the-art diagnostics, which are provided on an outpatient and occasionally inpatient basis, we also provide multidisciplinary care with drug therapies, assistive devices, supportive and palliative therapies.

Our team has a keen interest in clinical and basic research: we study disease mechanisms (e.g. MAXOMOD consortium), biomarkers for motor neuron disease and its early symptoms (e.g. premodiALS study), and develop self-initiated clinical trials translating findings from our neurobiology lab to the clinics (e.g., ROCK-ALS trial). In addition, we participate in industry-initiated clinical trials aiming to give every patient the opportunity to participate in a therapy trial. Our center coordinates several national and international research projects on ALS and participates in collaborative research activities of the German MND-NET.

The center is staffed with two study nurses and two residents, headed by the principal investigator Prof. Paul Lingor. We have access to the full infrastructure of the department, including a CSF laboratory and the biobank. In addition, further members of our group are available in the research lab.

Our overall goal is to provide state-of-the-art patient care and to make a contribution to translational research in ALS to improve the diagnosis and therapy of this devastating disorder.

Rechts der Isar Hospital of the Technical University Munich

Prof. Dr. B. Hemmer

Principal investigator

Prof. Dr. Paul Lingor

Contact information

Ismaninger Str. 22, 81675 München


Prof. Dr. Paul Lingor


+49 89 4140 8257

Website Visit the website


  • Multiomic ALS signatures highlight sex differences and molecular subclusters and identify the MAPK pathway as therapeutic target.

    Lucas Caldi Gomes, Sonja Hänzelmann, Sergio Oller, Mojan Parvaz, Fabian Hausmann, Robin Khatri, Melanie Ebbing, Constantin Holzapfel, Laura Pasetto, Stefano Fabrizio Columbro, Serena Scozzari, Marie Gebelin, Johanna Knöferle, Isabell Cordts, Antonia F. Demleitner, Laura Tzeplaeff, Marcus Deschauer, Claudia Dufke, Marc Sturm, Qihui Zhou, Pavol Zelina, Emma Sudria-Lopez, Tobias B. Haack, Sebastian Streb, Magdalena Kuzma-Kozakiewicz, Dieter Edbauer, R. Jeroen Pasterkamp, Endre Laczko, Hubert Rehrauer, Ralph Schlapbach, Christine Carapito, Valentina Bonetto, Stefan Bonn, Paul Lingor

    bioRxiv 2023.08.14.553180; doi:

  • Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.

    Witzel S, Maier A, Steinbach R, Grosskreutz J, Koch JC, Sarikidi A, Petri S, Günther R, Wolf J, Hermann A, Prudlo J, Cordts I, Lingor P, Löscher WN, Kohl Z, Hagenacker T, Ruckes C, Koch B, Spittel S, Günther K, Michels S, Dorst J, Meyer T, Ludolph AC; German Motor Neuron Disease Network (MND-NET). JAMA Neurol. 2022 Feb 1;79(2):121-130. doi: 10.1001/jamaneurol.2021.4893.

  • Challenges and opportunities for Multi-National Investigator-Initiated clinical trials for ALS: European and United States collaborations.

    Lingor P, Koch JC, Statland JM, Hussain S, Hennecke C, Wuu J, Langbein T, Ahmed R, Günther R, Ilse B, Kassubek J, Kollewe K, Kuttler J, Leha A, Lengenfeld T, Meyer T, Neuwirth C, Tostmann R, Benatar M. Amyotroph Lateral Scler Frontotemporal Degener. 2021 Aug;22(5-6):419-425. doi: 10.1080/21678421.2021.1879866. Epub 2021 Feb 3.

  • ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis.

    Lingor P, Weber M, Camu W, Friede T, Hilgers R, Leha A, Neuwirth C, Günther R, Benatar M, Kuzma-Kozakiewicz M, Bidner H, Blankenstein C, Frontini R, Ludolph A, Koch JC; ROCK-ALS Investigators. Front Neurol. 2019 Mar 27;10:293. doi: 10.3389/fneur.2019.00293.

  • Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis.

    Tönges L, Günther R, Suhr M, Jansen J, Balck A, Saal KA, Barski E, Nientied T, Götz AA, Koch JC, Mueller BK, Weishaupt JH, Sereda MW, Hanisch UK, Bähr M, Lingor P. Glia. 2014 Feb;62(2):217-32. doi: 10.1002/glia.22601. Epub 2013 Dec 6.

For other publications, see:

Restricted information

Serving population
Serving population

Approximately 5 mio. people in the larger area of Munich

Patient resources
Population based register


Clinic based register


Geographically matched controls


Number of spinal cord samples

We participate in the brain bank collection of the DZNE

Number of brain samples

We participate in the brain bank collection of the DZNE


Type ALS Patients Controls Other
DNA bank 300 1000
Serum bank 300 1000
Research activities
Clinical management research


Neuro epidemiology


Neuro physiology


Neuro imaging


Neuro psychology


Neuro pathology








Clinical Trials - Industry sponsored

Name Type Patients
CORT113176-652 Phase 2
ALXN1210-ALS-308 Phase 3
MT-1106-02 Phase 3
MT-1106-04 Phase 3
AB19001 Phase 3

Clinical Trials - Investigator initiated

Project lead at TUM

Name Type Patients
ROCK-ALS An international, multicenter, randomized, controlled, phase II clinical study to evaluate a novel disease-modifying treatment with the ROCK-inhibitor fasudil for ALS 120
SAFE-ROCK A monocenter, randomized, controlled phase Ib trial of the absolute bioavailability, safety and tolerability of an oral application of the ROCK inhibitor Fasudil in healthy participants 14
premodiALS A premotor disease signature for ALS (observational trial), multicenter, international 330
EARLY-ALS Analysis of EARLY symptoms in ALS (observational trial), multicenter, national 1000